This site is intended for UK healthcare professionals only

NEWS

 

Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

KEYTRUDA has received FDA approval for treatment of patients with locally advanced or metastatic urothelial carcinoma
1 September 2021
Cancer
FDA approves KEYTRUDA for locally advanced or metastatic urothelial carcinoma

KEYTRUDA has received FDA approval for treatment of patients with locally advanced or metastatic urothelial carcinoma in patients who are not eligible for any platinum-containing chemotherapy

Merck, known as MSD outside the United States and Canada, have announced a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S. The U.S. Food and Drug Administration (FDA) has converted this indication from an accelerated to a full (regular) approval. In addition, as part of the label update, this indication has been revised to be for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for any platinum-containing chemotherapy.

Previously, KEYTRUDA was indicated for the treatment of patients with locally advanced or mUC who were not eligible for cisplatin-containing chemotherapy and whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10), as determined by an FDA-approved test, or in patients who were not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication was approved under accelerated approval based on tumor response rate and duration of response. Continued approval was contingent upon verification and description of clinical benefit in confirmatory trials. The subsequent Phase 3 trial KEYNOTE-361, evaluating KEYTRUDA as monotherapy and in combination with chemotherapy for the first-line treatment of patients with advanced or mUC who were eligible for platinum-containing chemotherapy, did not meet its pre-specified dual primary endpoints of overall survival or progression-free survival, compared with standard of care chemotherapy.

This label update follows the FDA’s Oncologic Drugs Advisory Committee (ODAC) meetings held earlier this year as part of an industry-wide evaluation of indications based on accelerated approvals that have not met their post-marketing requirements. As previously announced, members voted (5-3) in favor of maintaining the accelerated approval of KEYTRUDA for its first-line bladder indication.

“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We are confident in the role KEYTRUDA will continue to play for these patients who have few other treatment options and are working with urgency to advance studies to help more patients living with bladder and other types of cancer.”

In addition to this first-line indication, KEYTRUDA is approved for the treatment of patients with locally advanced or mUC who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. KEYTRUDA is also approved for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Merck has an extensive clinical development program in bladder cancer and is advancing multiple studies evaluating KEYTRUDA as monotherapy and in combination with other anti-cancer therapies across multiple lines of therapy.

Visit the Bladder Interest Group news page to explore recent industry updates.

Latest News

Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male...

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...